Sophia Genetics Sa Stock Price, News & Analysis

SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in several upcoming investor conferences, including the Credit Suisse 30th Annual Healthcare Conference on November 11, the Piper Sandler 33rd Annual Healthcare Conference starting November 22, and the Evercore ISI HealthCONx Conference on November 30. Investors can access live and archived presentations through the company's Investors section on their website. SOPHiA GENETICS focuses on data-driven medicine, utilizing its cloud-based SOPHiA DDM™ Platform in over 780 institutions worldwide.

SOPHiA GENETICS (Nasdaq: SOPH) announced it will report Q3 financial results on November 10, 2021, before the market opens. Management will host a webcast at 8:30 a.m. ET to discuss results, business advancements, and future outlook. The SOPHiA DDM™ Platform, their cloud-based SaaS solution, is utilized by over 780 institutions globally, aiming to set data-driven medicine as a standard. The live audio will be available on the company’s Investors section of the website, with an archived replay afterwards.

SOPHiA GENETICS (Nasdaq: SOPH) has launched the SOPHiA Clinical Exome Solution v3, which enhances probe design and detection capabilities for investigating Mendelian diseases. This application combines a capture-based target enrichment kit with the SOPHiA DDM™ platform, achieving over 90% analytical sensitivity for CNV detection. Enhanced probe design allows for improved detection of rare disorders across the mitochondrial genome and 280 known disorder-causing genomic locations. This innovation aims to streamline data analysis and improve institutional resource efficiency.

SOPHiA GENETICS (NASDAQ: SOPH) reported Q2 2021 revenue of $10.2 million, a 72% increase Year-over-Year (YoY). The customer base grew to 780. The company raised approximately $217 million from its IPO and $20 million from a private placement. Q2 gross profit was $6.2 million, with a margin of 61%, down from 67% in Q2 2020. Operating expenses rose to $22.2 million, leading to a net loss of $18.4 million. For 2021, revenue guidance exceeds $39 million, projecting over 37% growth.

SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. The presentation is scheduled for 9:30 a.m. Eastern Time/3:30 p.m. Central European Time and will be accessible via a live and archived webcast on the company’s website.

The company is a leader in data-driven medicine and offers the SOPHiA DDM™ Platform, which supports over 780 institutions globally in analyzing complex data sets for healthcare and life sciences.

SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2021 financial results on September 9, 2021, before market open. The management will host a conference call at 8:30 a.m. ET to discuss these results, alongside business developments and future outlook. The company focuses on data-driven medicine and operates the SOPHiA DDM™ Platform, utilized by over 780 institutions globally. A live webcast of the call will be accessible in the 'Investors' section of their website, with an archived replay available post-event.

SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q2 2021 on September 9, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss these results, business developments, and future outlook. The company emphasizes its commitment to data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 780 healthcare institutions globally, reinforcing its strategic position in the healthcare technology landscape.

Dasa, Brazil's largest healthcare network, is expanding its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to launch the first decentralized HRD analytics solution in Latin America. This solution focuses on identifying cancer patients who may benefit from PARP inhibitors, promoting personalized therapies. With over 20 million patient interactions yearly, Dasa enhances its genomic capabilities using SOPHiA's platform, built on a collaboration that started in 2016. This innovation aims to improve patient outcomes through efficient data management and tailored treatment strategies.

SOPHiA GENETICS (Nasdaq: SOPH) has successfully closed its initial public offering, selling 13,000,000 ordinary shares at $18 each, generating gross proceeds of $234 million. Following this, the company also completed a private placement, issuing 1,111,111 ordinary shares to GE Healthcare for $20 million. The new shares began trading on the Nasdaq on July 23, 2021. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse were joint book-running managers for the IPO.